Skip to Content
A vastly improved search engine helps you find the latest on companies, business leaders, and news more easily.
Critical as they are, clinical trials are often bottlenecks for medical breakthroughs. While 70% of people say they would participate in such trials, few who could benefit do so, because enrollment is logistically complicated and geographically limited. Such hurdles help explain why just 3% of adult cancer patients get an investigational therapy, and why drug trials end up taking so long and becoming so expensive.  To tackle this unfortunate inefficiency, Tempus, a precision medicine company, unleashed its big-data tools to create the TIME trial program, which quickly connects patients, providers, and pharma companies, and facilitates clinical trial initiation in new locations (that is, close to a patient’s home). Since 2019, Tempus has identified more than 5,000 patients for trials—and it activates those patients’ trial sites in roughly 10 days, compared with the industry’s 20-week average. That’s precious time for drug companies, who pay to participate in Tempus’s network, and for cancer patients alike.
Courtesy of Tempus
Lists ranking Tempus
Change the World - 2021These companies use the creative tools of capitali...READ MOREview in list
Latest news for Tempus